BioNTech’s Pumitamig Low-Dose Surprise Steals ASCO Spotlight as Regulatory Path Sharpens
31.05.2026 - 10:10:52 | boerse-global.de
The most striking detail from BioNTech’s ASCO 2026 presentation wasn’t the high response rates – it was which dose delivered them. In the phase 2/3 ROSETTA Lung-02 trial, the lower of two tested doses of the bispecific antibody Pumitamig produced the stronger result: a confirmed overall response rate (cORR) of 72.7% in squamous non-small cell lung cancer (NSCLC) and 63.6% in non-squamous disease, compared with 68.4% and 57.1% respectively at the higher dose. Across all 40 evaluable patients, the disease control rate hit 100%.
That consistency held across PD-L1 expression levels. Patients with a TPS of 50% or higher saw a complete response, while even the PD-L1-negative subgroup managed a cORR of 47.6% – a figure that underscores the breadth of the dual mechanism. Developed with Bristol Myers Squibb, Pumitamig blocks both PD-L1 and VEGF-A, combining checkpoint inhibition with anti-angiogenesis in a single molecule.
The safety profile fell within expected bounds for this therapy class. Grade 3 or higher adverse events occurred in 48.8% of patients, and only 9.3% discontinued treatment due to side effects. No fatal events were reported.
Should investors sell immediately? Or is it worth buying BioNTech?
A faster path to approval
BioNTech and BMS have recalibrated their regulatory strategy following discussions with the FDA. The phase 3 trial, now expanded to roughly 1,260 patients, uses progression-free survival (PFS) as its primary endpoint instead of overall survival. That shift allows earlier data readouts and opens the door to accelerated approval. Overall survival remains a secondary endpoint.
Market reaction and analyst support
The BioNTech share closed Friday at €82.35 on XETRA, up 2.68% on the day and roughly 3.6% for the week. On a yearly basis the stock is nearly flat and still 19% below its 52-week high of €101.90. Yet the data fuelled after-hours gains and reinforced the bullish case from UBS, which upgraded the stock to Buy on May 27 and raised its price target from $117 to $135. The analyst consensus now sits at $125.45.
BioNTech is also signalling its own conviction through a billion-dollar American depositary share buyback programme – a move management typically reserves for moments of perceived undervaluation.
The hard numbers behind the transformation
The Mainz-based company holds a liquidity reserve of €13.71 billion, funding 15 planned phase 3 studies. But the transition from COVID vaccine pure-play to oncology powerhouse comes at a steep cost: first-quarter operating losses hit €494.6 million against revenue of just €118.1 million. Pumitamig’s ASCO performance provides the first concrete evidence that this expensive pivot may deliver. The third consistent global dataset – and the surprising efficacy of the lower dose – gives investors more than just data points; it gives a clearer line of sight to a registration filing.
Ad
BioNTech Stock: New Analysis - 31 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis BioNTech’s Aktien ein!
FĂĽr. Immer. Kostenlos.
